Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

NCT03223155 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
RADIATION: Stereotactic body radiation therapy

Sponsor

University of Chicago